<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139932</url>
  </required_header>
  <id_info>
    <org_study_id>P04272</org_study_id>
    <nct_id>NCT00139932</nct_id>
  </id_info>
  <brief_title>Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)</brief_title>
  <official_title>A Double-Blind Randomized, Parallel-Group, Multicenter Clinical Study to Compare the Efficacy and Tolerability of Tiotropium Bromide Alone vs. the Co-Administration of Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrated Therapeutics Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if the co-administration of formoterol fumarate&#xD;
      and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients&#xD;
      with COPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2005</start_date>
  <completion_date type="Actual">November 21, 2006</completion_date>
  <primary_completion_date type="Actual">November 21, 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effects of tiotropium bromide alone vs.the effect of tiotropium bromide and formoterol fumarate</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the effects of tiotropium bromide alone vs. the effects of co-administration of tiotropium bromide and formoterol fumarate on the change from baseline of the normalized area under the time curve (AUC) for FEV1 for the 0 hour to 4 hours post-morning dose at the last study visit.</description>
  </primary_outcome>
  <enrollment type="Actual">255</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol fumarate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a clinical history of COPD.&#xD;
&#xD;
          -  Subjects must be current cigarette smokers or ex-smokers who stopped smoking at least&#xD;
             3 months prior to screening visit (V1). Subjects must have a smoking history of at&#xD;
             least 10 pack-years (20 cigarettes per pack). Pack-years are calculated by multiplying&#xD;
             the average packs of cigarettes smoked per day times the number of years.&#xD;
&#xD;
          -  Subjects on stable inhaled corticosteroids are allowed to be enrolled and to remain on&#xD;
             the treatment throughout the study.&#xD;
&#xD;
          -  Subjects must be willing to give written informed consent and able to adhere to dose&#xD;
             and visit schedules.&#xD;
&#xD;
          -  Subjects must agree to inform their usual treating physician of their participation in&#xD;
             this study.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative urine pregnancy test&#xD;
             prior to the randomization of the study&#xD;
&#xD;
          -  Nonpregnant women of childbearing potential must be using a medically acceptable,&#xD;
             adequate form of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects have a current or past history of clinically relevant asthma.&#xD;
&#xD;
          -  Subjects quit smoking less than 3 months prior to the Screening visit (V1).&#xD;
&#xD;
          -  Subjects have required ventilator support for respiratory failure within the last&#xD;
             year.&#xD;
&#xD;
          -  Subjects have clinically significant lung disease other than COPD, e.g.,&#xD;
             bronchiectasis, sarcoidosis, pulmonary fibrosis, tuberculosis, etc.&#xD;
&#xD;
          -  Subjects have undergone lobectomy, pneumonectomy or lung volume reduction surgery.&#xD;
&#xD;
          -  Subjects have had lung cancer diagnosed or treated within the last five years.&#xD;
&#xD;
          -  Subjects require nasal continuous positive airway pressure (CPAP) or bi-level positive&#xD;
             airway pressure (Bi-PAP).&#xD;
&#xD;
          -  Subjects have initiated pulmonary rehabilitation within the past 3 months.&#xD;
&#xD;
          -  Subjects use oxygen &gt;= 2 liters per minute for &gt; 2 hours per day.&#xD;
&#xD;
          -  Subjects require chronic or prophylactic treatment with antibiotics.&#xD;
&#xD;
          -  Subjects have significant renal, hepatic, cardiovascular (including cor pulmonale),&#xD;
             metabolic, neurologic, hematologic, gastrointestinal, cerebrovascular or other&#xD;
             significant medical illness or disorder which, in the judgment of the Investigator,&#xD;
             may interfere with the study or require treatment which may affect the evaluation of&#xD;
             efficacy and safety of the study drug.&#xD;
&#xD;
          -  Subjects have clinically significant abnormalities on chest x-ray (other than evidence&#xD;
             of COPD) at the Screening visit or within the previous year.&#xD;
&#xD;
          -  Women are pregnant or breast-feeding.&#xD;
&#xD;
          -  Subjects cannot adhere to the concomitant medications restrictions and prohibitions.&#xD;
&#xD;
          -  Subjects have used any investigational product within 30 days, or 3 months for any&#xD;
             biologic of unknown half-life, prior to the Baseline Visit (V3).&#xD;
&#xD;
          -  Subjects are part of the staff or a family member of the staff personnel directly&#xD;
             involved with this study.&#xD;
&#xD;
          -  Subjects have chronic narrow-angle glaucoma.&#xD;
&#xD;
          -  Subjects have symptomatic prostatic hyperplasia or bladder-neck obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.merck.com/clinical-trials/policies-perspectives.html</url>
    <description>Click here to access a synopsis of the study results.</description>
  </link>
  <results_reference>
    <citation>Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009 Feb;6(1):17-25. doi: 10.1080/15412550902724073.</citation>
    <PMID>19229704</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

